Consolidation Immunotherapy in Locally Advanced NSCLC – Targeted Oncology
Medical Xpress |
Consolidation Immunotherapy in Locally Advanced NSCLC
Targeted Oncology Jyoti Patel, MD: This patient illustrates, really, what I've started to do in my practice. For patients who are eligible for checkpoint blockade because they don't have a history of autoimmune disease, they don't have HIV, and they're otherwise well … Researchers find promising treatment strategy for stage 1-3 NSCL cancer patients SU2C researchers find promising treatment strategy for stage 1-3 NSCL cancer patients |
